Redeye cuts its forecasts and Base Case following a Q4 with negative ARR growth yet improved EBITDA-CAPEX y/y. While a substantial improvement from the negative ARR trend seen in Q4 is necessary, management has several new initiatives to accelerate growth. Also, further cost cuts – targeting non-revenue generating costs – lowers the bar for profitability.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/